September 07, 2020

IBRI RESEARCH PUBLISHED: Presumption of Innocence for Beta Cells: Why are They Vulnerable Autoimmune Targets in Type 1 Diabetes?

Abstract It is increasingly appreciated that the pathogenic mechanisms of type 1 diabetes involve both the autoimmune aggressors and their beta cell targets, which engage in a conflicting dialogue...

September 02, 2020

IBRI IN THE NEWS: IBRI Names New President and CEO

Indianapolis - The Indiana Biosciences Research Institute has named Dr. Alan Palkowitz president and chief executive officer. IBRI says the research scientist will continue his work at the Indiana University...

September 02, 2020

Indiana Biosciences Research Institute Names Dr. Alan Palkowitz President and CEO

Indianaplis, Ind. - The Indiana Biosciences Research Institute (IBRI), a leading industry-inspired applied research institute, is pleased to announce that it has named Alan Palkowitz, PhD, as its new president...

August 28, 2020

IBRI RESEARCH PUBLISHED: Revisiting the Role of Inflammation in the Loss of Pancreatic ß-cells in T1DM

Islet inflammation (insulitis) in type 1 diabetes mellitus is triggered by a deleterious dialogue between β-cells and the immune system, inducing β-cell dysfunction and death. This concept, outlined in our...

August 19, 2020

IBRI IN THE NEWS: IBRI Licenses Rapid-Testing Technology for Infectious Diseases

Point-of-care testing is a critical tool in the battle against COVID-19, and researchers in Indiana are working around the clock to deliver rapid tests with high specificity. Since the...

August 10, 2020

IBRI IN THE NEWS: IBRI Moving Into 16 Tech Innovation Building 1

The Indiana Biosciences Research Institute will soon be relocating its headquarters to the new 16 Tech Innovation Building 1 in a move expected to open more doors for collaboration. Launched...

August 05, 2020

IBRI RESEARCH PUBLISHED: Optimization of Methods for the Production and Refolding of Biologically Active Disulfide Bond-Rich Antibody Fragments in Microbial Hosts

Abstract Antibodies have been used for basic research, clinical diagnostics, and therapeutic applications. Escherichia coli is one of the organisms of choice for the production of recombinant antibodies. Variable...

July 31, 2020

IBRI RESEARCH PUBLISHED: Circulating unmethylated CHTOP and INS DNA fragments provide evidence of possible islet cell death in youth with obesity and diabetes

Abstract Identification of β cell death prior to the onset of type 1 diabetes (T1D) or type 2 diabetes (T2D) might allow for interventions to protect β cells and...

July 30, 2020

IBRI IN THE NEWS: IBRI Technologies Lead to Handheld Analyzing Device

Indianapolis - The Indiana Biosciences Research Institute (IBRI) is marking a milestone: the team is licensing its first technology, and as a result, giving birth to a startup based in...

July 25, 2020

IBRI RESEARCH PUBLISHED: Targeting Polyamine Biosynthesis to Stimulate Beta Cell Regeneration in Zebrafish

Abstract Type 1 diabetes (T1D) is a disease characterized by destruction of the insulin-producing beta cells. Currently, there remains a critical gap in our understanding of how to reverse...

First 1 2 3 4 5  ... Last 
2020 Annual Report cover

The IBRI 2020 Annual Report is now available. The report theme, ‘Shaping the Future of Translational Science,’ reflects the IBRI’s commitment to turning scientific discovery into improved outcomes for patients.